Skip to main content

Table 3 Correlations between TILs and pCR in neoadjuvant treated TNBCs

From: Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers

Variables Univariate analysis Multivariate analysis
OR 95% CI P-value OR 95% CI P-value
ITILs (per 10%) 1.10 1.04–1.16 0.001* 1.06 1.00-1.12 0.04*
STILs (per 10%) 1.07 1.03–1.10 0.0001* 1.05 1.02-1.09 0.006*
Age (years) (< 50 vs. ≥50) 0.51 0.27–0.95 0.04* 0.65 0.31-1.35 0.25
Histological grade (2 vs. 3) 2.74 1.11–6.80 0.03* 1.02 0.34-3.08 0.98
Tumor size (cm) (≤2 vs. 2–5 vs. > 5) 1.30 0.74–2.29 0.37 1.30 0.68–2.47 0.43
Nodal status (negative vs. positive) 0.93 0.48–1.81 0.84 1.52 0.72–3.22 0.28
LVI (negative vs. positive) 0.06 0.01–0.26 0.0001* 0.07 0.02-0.29 0.0001*
Ki-67 index 1.03 1.01–1.04 0.001* 1.02 1.006-1.04 0.009*
NAC (Anthracycline + paclitaxel vs. paclitaxel + platinum) 0.83 0.37–1.87 0.65 1.10 0.41–2.94 0.85
  1. Abbreviations: pCR pathological complete response, TNBCs triple-negative breast cancers, sTILs stromal tumor-infiltrating lymphocytes, iTILs intratumoral tumor-infiltrating lymphocytes, LVI lymphovascular invasion, NAC neoadjuvant chemotherapy, OR odds ratio, 95% CI 95% confidence interval
  2. *The P value is significant